Loading...
 
Translate Register Log In Login with facebookLogin and Register

Recent Diabetics treated by supplementation which achieved 60 ng of vitamin D – RCT Sept 2014

A randomised controlled trial of high dose vitamin D in recent-onset type 2 diabetes.

Diabetes Res Clin Pract. 2014 Sep 28. pii: S0168-8227(14)00395-7. doi: 10.1016/j.diabres.2014.08.030. Epub ahead of print
Elkassaby S1, Harrison LC2, Mazzitelli N1, Wentworth JM3, Colman PG4, Spelman T5, Fourlanos S6.

VitaminDWiki Summary

Supplementation with 6,000 IU for 6 months

Baseline 3 months6 months
Vitamin D 24 ng 60 ng 51 ng
fasting plasma glucose -0.4 0 vs placebo
post-prandial blood glucose -.3
placebo +0.8
0 vs placebo

Why?

  1. 60 ng helped, but later 50 ng did not
  2. Vitamin D drop from month 3 to month 6
    Do not recall seeing this in RCT with other diseases
  • Perhaps something changed in the gut which reduced the bio-availability
    Example: chime spend less time in the gut in months 3-6 ==> less absoption of vitamin D
  • Perhaps the trial was run during a single year and the last 3 months were during the winter - when D levels normally drops
  • If the vitamin D supplementation had been raised in months 3-6 would the benefits would have been maintained?


AIMS:
Vitamin D insufficiency has been associated with impaired pancreatic beta-cell function. We aimed to determine if high dose oral vitamin D3 (D) improves beta-cell function and glycaemia in type 2 diabetes.
METHODS:
Fifty adults with type 2 diabetes diagnosed less than 12 months, with normal baseline serum 25-OH D (25D), were randomised to 6000IU D (n=26) or placebo (n=24) daily for 6 months. Beta-cell function was measured by glucagon-stimulated serum C-peptide (delta C-peptide DCP, nmol/l). Secondary outcome measures were fasting plasma glucose (FPG), post-prandial blood glucose (PPG), HbA1c and insulin resistance (HOMA-IR).
RESULTS:
In the D group, median serum 25D (nmol/l) increased from 59 to 150 (3 months) and 128 (6 months) and median serum 1,25D (pmol/l) from 135 to 200 and 190. After 3 months, change in DCP from baseline in D (+0.04) and placebo (-0.08) was not different (P=0.112).

However, change in FPG (mmol/l) was significantly lower in D (-0.40) compared to placebo (+0.1) (P=0.007), as was the change in PPG in D (-0.30) compared to placebo (+0.8) (P=0.005). Change in HbA1c (%) between D (-0.20) and placebo (-0.10) was not different (P=0.459). At 6 months, changes from baseline in DCP, FPG, PPG and HbA1c were not different between groups.
CONCLUSION:
Oral D3 supplementation in type 2 diabetes was associated with transient improvement in glycaemia, but without a measurable change in beta-cell function this effect is unlikely to be biologically significant. High dose D3 therefore appears to offer little or no therapeutic benefit in type 2 diabetes.

Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.


PMID: 25438937


See also VitaminDWiki

  • Diabetes is 5X more frequent far from the equator
  • Children getting 2,000 IU of vitamin D are 8X less likely to get Type 1 diabetes
  • Obese people get less sun / Vitamin D - and also vitamin D gets lost in fat
  • Sedentary people get less sun / Vitamin D
  • Worldwide Diabetes increase has been concurrent with vitamin D decrease and air conditioning
  • Elderly get 4X less vitamin D from the same amount of sun
        Elderly also spend less time outdoors and have more clothes on
  • All items in category Diabetes and Vitamin D 414 items: both Type 1 and Type 2

Vitamin D appears to both prevent and treat diabetes

  • Appears that >2,000 IU will Prevent
  • Appears that >4,000 IU will Treat , but not cure
  • Appears that Calcium and Magnesium are needed for both Prevention and Treatment
        which are just some of the vitamin D cofactors


See any problem with this page? Report it (FINALLY WORKS)